Dapagliflozin vs Pembrolizumab

Dapagliflozin vs Pembrolizumab: Overview

This comparison examines the pharmacological differences between Dapagliflozin and Pembrolizumab.

Mechanism of Action

Dapagliflozin: Selective SGLT2 inhibitor reducing renal glucose and sodium reabsorption.

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Pharmacokinetics

Half-life: Dapagliflozin — 12.9 hours; Pembrolizumab — 26 days.

Chemical Properties

Molecular Formula: Dapagliflozin — C21H25ClO6.

Molecular Weight: Dapagliflozin — 408.8730 g/mol.

Type: Dapagliflozin — Small molecule; Pembrolizumab — Antibody.